Known targets — ChEMBL curated mechanism
ACHESCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Gluconic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gluconic Acid SCHEMBL887105 | 0.97 | LMNA (0.59) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| SCHEMBL3385393 | 0.91 | LMNA (0.47) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL2229853 | 0.86 | LMNA (0.65) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL3710793 | 0.86 | LMNA (0.65) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL826558 | 0.84 | LMNA (0.62) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL547729 | 0.84 | LMNA (0.62) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL14662536 | 0.84 | LMNA (0.77) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| SCHEMBL10596732 | 0.82 | PDE4A (0.47) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| Silver SCHEMBL18889837 | 0.82 | LMNA (0.58) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL377417 | 0.82 | LMNA (0.74) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| JP-62169746-A | — | — | None | — | — | JP | disclosed |
| JP-59225140-A | — | — | None | — | — | JP | disclosed |
| JP-6192108-A | — | — | None | — | — | JP | disclosed |
| US-12605327-B2 | Hair cosmetic compositions | L'OREAL (FR) | 2026-04-21 | — | — | US | disclosed |
| WO-2025094212-A1 | STABLE AQUEOUS COMPOSITION OF CALCIUM GLUCONATE | EXTROVIS AG (CH) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025094212-A1 | STABLE AQUEOUS COMPOSITION OF CALCIUM GLUCONATE | EXTROVIS AG (CH) | 2025-05-08 | — | — | WO | disclosed |
| US-20240299446-A1 | COMPOSITION FOR PREVENTING, TREATING OR IMPROVING CALCIUM RELATED DEGENERATIVE DISEASES, OSTEOPOROSIS OR CANCERS COMPRISING SIGMA ANTI-BONDING MOLECULE CALCIUM GLUCONATE | LEE KYU HEON (CA) | 2024-09-12 | — | — | US | disclosed |
| US-20240145031-A1 | Methods and devices for drug repositioning and drug repurposing as nuclear receptor modulators | Precision Medicine Lab (NL) | 2024-05-02 | — | — | US | disclosed |
| CN-116966143-A | Emulsion composition comprising gel particles with colloidal coating | 株式会社爱茉莉太平洋 | 2023-10-31 | — | — | CN | disclosed |
| US-20090104339-A1 | METHOD FOR PREPARING CALCIUM GLUCONATE | PURAC BIOCHEM B.V. (NL) | 2009-04-23 | — | — | US | disclosed |
| US-20090104339-A1 | METHOD FOR PREPARING CALCIUM GLUCONATE | PURAC BIOCHEM B.V. (NL) | 2009-04-23 | — | — | US | disclosed |
| US-20040253345-A1 | Method for preparing calcium gluconate | PURAC BIOCHEM B.V. (NL) | 2004-12-16 | — | — | US | disclosed |
| EP-1434869-A1 | METHOD FOR PREPARING CALCIUM GLUCONATE | PURAC BIOCHEM N.V. (NL) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003031635-A1 | METHOD FOR PREPARING CALCIUM GLUCONATE | PURAC BIOCHEM B.V. (NL) | 2003-04-17 | — | — | WO | disclosed |
| EP-0582396-B1 | Taste-masking composition of bitter pharmaceutical agents | PFIZER (US) | 2001-01-03 | — | — | EP | disclosed |
| JP-H06192108-A | CALCIUM GLUCONATE ORAL SOLUTION | KANEBO LTD | 1994-07-12 | — | — | JP | disclosed |
| EP-0582396-A1 | Taste-masking composition of bitter pharmaceutical agents | PFIZER INC. (US) | 1994-02-09 | — | — | EP | disclosed |
| JP-S62169746-A | N-TYPE CRYSTAL OF NOVEL CALCIUM GLUCONATE | FUJISAWA PHARMACEUT CO LTD | 1987-07-25 | — | — | JP | disclosed |
| JP-S59225140-A | PREPARATION OF CALCIUM GLUCONATE | TOWA KASEI KOGYO KK | 1984-12-18 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605327-B2 | Hair cosmetic compositions | DSG1, ALG3, DEGS1 | LMNA 626/4885PDE4A 1475/4885USP2 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.